Verition Fund Management’s Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A BSX.PRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-1,000,000
Closed -$1.17M 3259
2022
Q1
$1.17M Hold
1,000,000
0.01% 1353
2021
Q4
$1.14M Buy
+1,000,000
New +$114M 0.01% 1208

Other funds holding BSX.PRA

Verition Fund Management's BSX.PRA Position: Q2 2022 in Review

Verition Fund Management sold out of Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A (BSX.PRA) in Q2 2022, closing a stake of 1,000,000 shares — an estimated $1.17M sold.

Verition Fund Management first reported a position in BSX.PRA in Q4 2021 and held it in 2 quarters. The position peaked at $1.17M in Q1 2022. 52 funds tracked by Wall St. Rank hold BSX.PRA as of Q2 2022.

  • Verition Fund Management reported no remaining Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position as of Q2 2022 after selling out during the quarter.
  • Verition Fund Management sold 1,000,000 Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A shares in Q2 2022, an estimated $1.17M.
  • Verition Fund Management first reported a position in Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A in Q4 2021 and held it in 2 quarters.
  • Verition Fund Management's Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position peaked at $1.17M in Q1 2022.
  • 52 funds tracked by Wall St. Rank held Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A as of Q2 2022.

Based on Verition Fund Management's 13F filing for Q2 2022, filed 15 Aug 2022.